Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody

The HIV-1 fusion peptide, comprising 15 to 20 hydrophobic residues at the N terminus of the Env-gp41 subunit, is a critical component of the virus-cell entry machinery. Here, we report the identification of a neutralizing antibody, N123-VRC34.01, which targets the fusion peptide and blocks viral ent...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Science (American Association for the Advancement of Science) 2016-05, Vol.352 (6287), p.828-833
Hauptverfasser: Kong, Rui, Xu, Kai, Zhou, Tongqing, Acharya, Priyamvada, Lemmin, Thomas, Liu, Kevin, Ozorowski, Gabriel, Soto, Cinque, Taft, Justin D., Bailer, Robert T., Cale, Evan M., Chen, Lei, Choi, Chang W., Chuang, Gwo-Yu, Doria-Rose, Nicole A., Druz, Aliaksandr, Georgiev, Ivelin S., Gorman, Jason, Huang, Jinghe, Joyce, M. Gordon, Louder, Mark K., Ma, Xiaochu, McKee, Krisha, O'Dell, Sijy, Pancera, Marie, Yang, Yongping, Blanchard, Scott C., Mothes, Walther, Burton, Dennis R., Koff, Wayne C., Connors, Mark, Ward, Andrew B., Kwong, Peter D., Mascola, John R.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The HIV-1 fusion peptide, comprising 15 to 20 hydrophobic residues at the N terminus of the Env-gp41 subunit, is a critical component of the virus-cell entry machinery. Here, we report the identification of a neutralizing antibody, N123-VRC34.01, which targets the fusion peptide and blocks viral entry by inhibiting conformational changes in gp120 and gp41 subunits of Env required for entry. Crystal structures of N123-VRC34.01 liganded to the fusion peptide, and to the full Env trimer, revealed an epitope consisting of the N-terminal eight residues of the gp41 fusion peptide and glycan N88 of gp120, and molecular dynamics showed that the N-terminal portion of the fusion peptide can be solvent-exposed. These results reveal the fusion peptide to be a neutralizing antibody epitope and thus a target for vaccine design.
ISSN:0036-8075
1095-9203
DOI:10.1126/science.aae0474